Hanson J W, Myrianthopoulos N C, Harvey M A, Smith D W
J Pediatr. 1976 Oct;89(4):662-8. doi: 10.1016/s0022-3476(76)80414-3.
The fetal hydantoin syndrome is a variable pattern of altered growth and performance which includes unusual facies, distal phalangeal hyoplasia, and other defects occurring in some infants exposed in utero to hydantoins. A prospective study of 35 infants exposed prenatally to this class of anticonvulsants showed that 11% had sufficient features to be classified as having the fetal hydantoin syndrome. An additional 31% displayed some features compatible with the prenatal effects of hydantoins. A case-control study of 104 infants whose mothers received hydantoins during pregnancy supports these conclusions. Reduction of intellectual ability in infants with the fetal hydantoin syndrome is the area of greatest concern. Women being treated with hydantoin anticonvulsants should be told of the nature and magnitude of risks to the developing fetus before considering a pregnancy.
胎儿苯妥英综合征是一种生长和发育改变的可变模式，包括特殊面容、远端指骨发育不全以及其他一些在子宫内接触苯妥英类药物的婴儿所出现的缺陷。一项对35名产前接触此类抗惊厥药物的婴儿的前瞻性研究表明，11%的婴儿具有足够特征被归类为患有胎儿苯妥英综合征。另外31%表现出一些与苯妥英类药物产前影响相符的特征。一项对104名母亲在孕期服用苯妥英类药物的婴儿的病例对照研究支持了这些结论。胎儿苯妥英综合征患儿智力能力下降是最令人担忧的方面。在考虑怀孕之前，应告知正在接受苯妥英类抗惊厥药物治疗的女性胎儿发育所面临风险的性质和程度。
